Logo

Roche’s Lunsumio (mosunetuzumab) Receives EC’s Approval for the Treatment of Relapsed or Refractory Follicular Lymphoma

Share this
Roche’s Lunsumio (mosunetuzumab) Receives EC’s Approval for the Treatment of Relapsed or Refractory Follicular Lymphoma

Roche’s Lunsumio (mosunetuzumab) Receives EC’s Approval for the Treatment of Relapsed or Refractory Follicular Lymphoma

Shots:

  • The EC has granted conditional marketing authorization for Lunsumio to treat adult patients with r/r FL who have received 2 prior systemic therapies
  • The approval was based on the P-I/II (GO29781) study evaluating the safety, efficacy & PK of Lunsumio which showed high CR rates & maintained responses for 18mos. with favorable tolerability, m-DoR (22.8mos.) after a median follow-up of 18.3mos., CR rate (60%), ORR (80%), and CRS (39%) which were generally low grade & cleared after treatment
  • The 2 P-III (CELESTIMO & SUNMO) studies are now being conducted for Lunsumio as part of a comprehensive development programme i.e., Lunsumio + lenalidomide as 2L+ FL & Lunsumio + Polivy (polatuzumab vedotin) in 2L+ DLBCL

Ref: Globenewswire | Image: Roche

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions